Longer Survival and Preserved Liver Function after Proton Beam Therapy for Patients with Unresectable Hepatocellular Carcinoma.
Longer Survival and Preserved Liver Function after Proton Beam Therapy for Patients with Unresectable Hepatocellular Carcinoma.
复制标题
DOI：
10.3390/curroncol30040296
复制
发表时间：
2023-03-30
期刊：
影响因子：
--
通讯作者：
中科院分区：
文献类型：
--
作者：
背景：最近有报道称，质子束治疗（PBT）在不可切除的肝细胞癌（HCC）患者中获得了极好的肿瘤控制和最小的毒性。研究了射频消融（RFA）联合经导管动脉化疗栓塞（TACE）治疗较大的HCC。本研究旨在评价PBT与TACE联合RFA治疗不可切除HCC的疗效。方法：回顾性分析70例手术切除或RFA单药难以控制的肝癌患者，24例采用PBT治疗，46例采用TACE联合RFA治疗。治疗效果评估为局部无进展生存期（PFS）和总生存期（OS）。结果：PBT + TACE + RFA组60个月局部PFS均大于65%。经PBT治疗的患者在治疗后60个月的总生存率为82%。相比之下，TACE + RFA治疗组的OS为28%。在比较不同严重程度慢性肝病患者的ALBI评分变化时，pbt治疗患者的评分维持在基线水平；而TACE + rfa治疗的患者在治疗后病情加重。结论：在不可切除的HCC患者中，PBT通过保留非肿瘤肝组织，在OS方面可能比TACE + RFA治疗有更好的疗效。
Background: Proton beam therapy (PBT) has been recently reported to achieve excellent tumor control with minimal toxicity in patients with unresectable hepatocellular carcinoma (HCC). Radiofrequency ablation (RFA) combined with transcatheter arterial chemoembolization (TACE) was investigated for larger HCC. This study was designed to evaluate the therapeutic effect of PBT on unresectable HCC in comparison with TACE combined with RFA. Methods: We retrospectively analyzed 70 patients with HCC which was difficult to control by surgical resection or RFA monotherapy, 24 patients treated with PBT and 46 patients with TACE plus RFA. The therapeutic effects were assessed as local progression-free survival (PFS) and overall survival (OS). Results: The local PFS was more than 65% in 60 months for PBT and TACE plus RFA. The patients treated with PBT showed 82% OS at 60 months post-treatment. In contrast, those treated with TACE plus RFA showed 28% OS. When comparing the changes of ALBI scores in patients with different severities of chronic liver disease, the scores of PBT-treated patients were maintained at the baseline; however, those of TACE plus RFA-treated patients worsened after the treatments. Conclusions: The results indicated that PBT may show better benefits than TACE plus RFA therapy in terms of OS in patients with unresectable HCC by sparing the non-tumor liver tissues.
登录
查看更多内容
DOI：
10.1186/1748-717x-8-48
发表时间：
2013-03-05
期刊：
Radiation oncology (London, England)
影响因子：
--
作者：
Toramatsu C;Katoh N;Shimizu S;Nihongi H;Matsuura T;Takao S;Miyamoto N;Suzuki R;Sutherland K;Kinoshita R;Onimaru R;Ishikawa M;Umegaki K;Shirato H
通讯作者：
Shirato H
影响因子：
25.7
作者：
Kim, Tae Hyun;Koh, Young Hwan;Park, Joong-Won
通讯作者：
Park, Joong-Won
影响因子：
3.8
作者：
Miksad, Rebecca A.;Ogasawara, Sadahisa;Piscaglia, Fabio
通讯作者：
Piscaglia, Fabio
影响因子：
5.2
作者：
Hatzidakis, Adam;Mueller, Lukas;Krokidis, Miltiadis;Kloeckner, Roman
通讯作者：
Kloeckner, Roman
DOI：
10.1016/j.ijrobp.2009.02.030
发表时间：
2010-02-01
影响因子：
7
作者：
Sugahara, Shinji;Oshiro, Yoshiko;Tokuuye, Koichi
通讯作者：
Tokuuye, Koichi